- Home
- DHIL vs LXRX Comparison
DHIL vs LXRX Comparison
Compare DHIL & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- LXRX
- Stock Information
- Founded
- DHIL 1990
- LXRX 1995
- Country
- DHIL United States
- LXRX United States
- Employees
- DHIL N/A
- LXRX N/A
- Industry
- DHIL Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- LXRX Health Care
- Exchange
- DHIL Nasdaq
- LXRX Nasdaq
- Market Cap
- DHIL 430.4M
- LXRX 352.5M
- IPO Year
- DHIL 1995
- LXRX 2000
- Fundamental
- Price
- DHIL $150.15
- LXRX $0.71
- Analyst Decision
- DHIL
- LXRX Buy
- Analyst Count
- DHIL 0
- LXRX 2
- Target Price
- DHIL N/A
- LXRX $6.00
- AVG Volume (30 Days)
- DHIL 17.7K
- LXRX 5.4M
- Earning Date
- DHIL 11-04-2024
- LXRX 11-12-2024
- Dividend Yield
- DHIL 4.00%
- LXRX N/A
- EPS Growth
- DHIL 21.33
- LXRX N/A
- EPS
- DHIL 17.67
- LXRX N/A
- Revenue
- DHIL $145,795,446.00
- LXRX $5,229,000.00
- Revenue This Year
- DHIL N/A
- LXRX $842.94
- Revenue Next Year
- DHIL N/A
- LXRX $19.76
- P/E Ratio
- DHIL $8.50
- LXRX N/A
- Revenue Growth
- DHIL 5.76
- LXRX 886.60
- 52 Week Low
- DHIL $135.44
- LXRX $0.62
- 52 Week High
- DHIL $173.25
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- DHIL 25.46
- LXRX 36.95
- Support Level
- DHIL $158.02
- LXRX $0.66
- Resistance Level
- DHIL $160.95
- LXRX $0.85
- Average True Range (ATR)
- DHIL 3.01
- LXRX 0.10
- MACD
- DHIL -1.83
- LXRX 0.02
- Stochastic Oscillator
- DHIL 5.65
- LXRX 23.67
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.